Neuronetics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024
For the full year 2024, the Company expects total worldwide revenue to be between $78.0 million and $80.0 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.61 USD | +3.57% | +3.98% | -10.00% |
May. 15 | Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents | CI |
May. 14 | William Blair Upgrades Neuronetics to Outperform From Market Perform | MT |
1st Jan change | Capi. | |
---|---|---|
-10.00% | 78.23M | |
+12.15% | 227B | |
+14.90% | 197B | |
+18.22% | 141B | |
+29.15% | 110B | |
+1.52% | 64.15B | |
+16.92% | 53.72B | |
+6.33% | 51.75B | |
+10.93% | 45.2B | |
+5.87% | 37.37B |